Show: Training Data · Publisher: Sequoia Capital · Host: Sonya Huang, Pat Grady
Episode URL: https://pscrb.fm/rss/p/traffic.megaphone.fm/CPUAI9345244137.mp3?updated=1745875147
Publish date: 2025-04-29
Duration: NAs
Default source credibility: HIGH — Sequoia partners interview frontier-lab founders + F500 AI buyers. VC-hosted — portfolio-company framing on recommendations; named guest metrics stay HIGH. Peer-tier to No Priors in quality.
- Isomorphic Labs aims to solve all diseases using AI, focusing on creating a general drug design engine applicable across various disease areas.
- Max Yoderberg highlights the importance of generative models and agents in navigating the vast space of potential drug molecules, emphasizing the need for models like AlphaFold3 to understand molecular interactions.
- The company’s partnerships with Eli Lilly and Novartis demonstrate significant progress in applying AI to challenging drug design problems, with a focus on immunology and oncology.
Extracted quotes
| # | Credibility | Speaker | Org | Timestamp | Topic | Quote |
|---|---|---|---|---|---|---|
| 1 | HIGH | Max Yoderberg (Chief AI Officer) | Isomorphic Labs | 00:10 | 01-ai-native-landscape | We have set up the company from day one to really go after this big ambition. This isn’t about developing therapeutics for a particular indication or particular target. It’s really thinking about how do we create a very general drug design engine with AI, something that we can apply to not just a single target or even a single modality, but we can apply this again and again across any different disease area. |
| 2 | HIGH | Max Yoderberg (Chief AI Officer) | Isomorphic Labs | 37:51 | 01-ai-native-landscape | There are so many bottlenecks throughout this whole design and development space. Drug development is, how do we start to approach clinical trials? How should we test these drugs out in people? How can we do this in a really timely manner but still a really safe manner. |
| 3 | HIGH | Max Yoderberg (Chief AI Officer) | Isomorphic Labs | 53:07 | 01-ai-native-landscape | We’re making amazing progress on our drug design programs. AI designed assets, these molecules, get into clinical phase, how can we actually start to think about engaging in that clinical development to get these molecules to people as fast and as safely as possible because there’s so much unmet medical need. |
Per-quote detail
1. Max Yoderberg — Isomorphic Labs (00:10)
We have set up the company from day one to really go after this big ambition. This isn’t about developing therapeutics for a particular indication or particular target. It’s really thinking about how do we create a very general drug design engine with AI, something that we can apply to not just a single target or even a single modality, but we can apply this again and again across any different disease area.
- Credibility: HIGH — Named exec at identifiable org with specific claim about company’s ambition and approach.
- Topic tag:
01-ai-native-landscape
2. Max Yoderberg — Isomorphic Labs (37:51)
There are so many bottlenecks throughout this whole design and development space. Drug development is, how do we start to approach clinical trials? How should we test these drugs out in people? How can we do this in a really timely manner but still a really safe manner.
- Credibility: HIGH — Named exec at identifiable org with specific claim about challenges in drug development.
- Topic tag:
01-ai-native-landscape
3. Max Yoderberg — Isomorphic Labs (53:07)
We’re making amazing progress on our drug design programs. AI designed assets, these molecules, get into clinical phase, how can we actually start to think about engaging in that clinical development to get these molecules to people as fast and as safely as possible because there’s so much unmet medical need.
- Credibility: HIGH — Named exec at identifiable org with specific claim about progress in clinical development.
- Topic tag:
01-ai-native-landscape
Extracted 2026-04-14T20:20:22 via scripts/podcast_mine.py (MLX mlx-community/Qwen2.5-32B-Instruct-4bit).